Intended for healthcare professionals

References w1 - w20

Posted as supplied by the author


w1. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Herbert et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomisde controlled trials. BMJ 2005;330:396-399.

w2. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005;330:385-8.

w3. Agency for Health Care Policy and Research Treatment of depression: newer

pharmacotherapies. San Antonio, Texas: Texas University Health Science Center, 1999.

w4. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants : Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297-303.

w5. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 2000;176:421-428.

w6. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health treatment of depression collaborative research program. Archives of General Psychiatry 1989;46:971-982.

w7. Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression : general practice placebo-controlled trial. Journal of Affective Disorders 1988;14:83-95.

w8. Greenberg RP, Fisher S. Mood-mending medicines: Probing drug, psychotherapy and placebo solutions. In Greenberg RP, Fisher S (Editors), From Placebo to Panacea. P 115-172. New York: John Wiley & Sons, 1997.

w9. Antonuccio DO, Danton WG, DeNelsky GY, Greenberg RP, Gordon JS. Raising questions about antidepressants. Psychotherapy and Psychosomatics 1999;68:3-14.

w10. Moncrieff J. Are antidepressants over-rated? A review of methodological problems in antidepressant trials. JNMD 2001;189:288-295.

w11. Medical Research Council. Clinical trial of the treatment of depressive illness. BMJ 1965;1:881-886.

w12. Raskin A, Schulterbrandt JG, Reatig N, Chase C, McKeon JJ. Differential response to chlorpromazine, imipramine and placebo. Archives of General Psychiatry 1970;23:164-173.

w13. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus. Association between antidepressant prescribing and suicide in Australia, 1991-2000:trend analysis. BMJ 2003; 326:1008-1011.

w14. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States 1985-1999. J Clin Psychiatry 2004; 65:1456-62

w15. Gunnel D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329:34-38.

w16. Murphy GE, Wetzel RD. Suicide risk by birth cohort in the United States, 1949 to 1974. Arch Gen Psychiatry 1980;37:519-23

w17. Draper BM. Decline in older suicides in Australia was much greater before antidepressants were introduced. BMJ Rapid Responses 2003;

w18. Walsh D. Antidepresasants and suicide in Ireland. BMJ Rapid Responses 2004; Statistics available courtesy of Irish Association of Suicidology at

w19. Storosum JG, van Zwieten BJ, van den brink W, gersons BP, broekmans AW. Suicide risk in placebo controlled studies of major depression. Am J Psychiatry 2002; 158:1271-75.

w20. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790-92.